Study: Obese teens taking popular weight loss drugs less likely to consider suicide

JERUSALEM, Israel — Drugs like Ozempic and Wegovy may provide a surprising, life-saving benefit for the youngest patients taking these diabetes and weight loss medications. Researchers in Israel have found that teenagers using glucagon-like peptide 1 receptor (GLP-1) agonists may have fewer suicidal thoughts and are less likely to attempt self-harm.

This finding comes at a time when concerns about the mental health of adolescents are at an all-time high, and the use of weight loss drugs is becoming increasingly common among patients of all ages. The study, published in JAMA Pediatrics, specifically looked at this class of medications, which include brands like Ozempic, Wegovy, and Mounjaro. Originally created as an effective treatment for diabetes, these drugs have gained popularity for their additional ability to help people lose weight by reducing appetite and slowing digestion.

Researchers analyzed the medical records of nearly 7,000 adolescents between 12 and 18 years-old who were diagnosed with obesity. They compared two groups: those who were prescribed GLP1R medications and those who were given lifestyle interventions like diet and exercise advice without medication.

The striking results revealed that teens who took GLP1R drugs had a 33% lower risk of having suicidal thoughts or attempts over the course of a year compared to those who didn’t take the medication. This difference persisted even when researchers looked at data for up to three years.

The study’s findings are particularly relevant given the rising rates of obesity among young people. According to recent data, more than 124 million children and adolescents worldwide are affected by obesity, a number that has increased dramatically over the past few decades.

While the exact reasons for the reduced suicide risk aren’t clear, researchers have several theories. One possibility is that successful weight loss itself leads to improved mental health and self-esteem. Another theory is that the medications may have direct effects on the brain, potentially influencing mood and behavior.

It’s important to note that the study found some expected side-effects of the medications. Teens taking GLP1R drugs were more likely to experience gastrointestinal symptoms like nausea and vomiting. However, they had a lower risk of acute pancreatitis, a potentially serious condition that has been associated with these medications in some cases.

The researchers caution that while these results are promising, more studies are necessary to confirm the findings and understand the long-term effects of these medications on adolescent mental health. They also stress that medication should be part of a comprehensive approach to treating obesity that includes diet, exercise, and behavioral support.

As the debate over the use of weight loss medications in young people continues, this study adds an important piece to the puzzle. It suggests that for some teens struggling with obesity, these drugs might offer benefits that go beyond just shedding pounds.